has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients. DAAN Biotherapeutics has successfully established a proprietary pipeline for ...

Byoung Chul Cho, MD, the CEO of DAAN Biotherapeutics, stated, "We will continue to develop state-of-the-art antibodies targeting solid tumors and collaborate with global pharmaceutical companies in ...